| INTRODUCTION
Allergic symptoms to peanut are mediated by IgE antibodies against specific components of peanut, of which Ara h 1, 2, 3 and 6 are generally considered to be the major allergens. Other components are Ara h 8 (Bet v 1 homologue) and Ara h 9 (lipid transfer protein), but sensitization to these molecules is well established to be indirect (cross-reactivity). However, specific IgE against peanut allergens is also found in serum of subjects that tolerate peanuts. Although in tolerant but sensitized subjects IgE levels are usually lower than in peanut allergic patients, they show large overlap between both groups.
Why similar IgE levels sometimes translate into tolerance and sometimes into clinical allergy is still not fully understood. In addition, it is also not clear why symptom severity varies between patients. 1 Altogether, this limits the prognostic value of serum IgE tests and their contribution to the diagnosis of peanut allergy. Traditionally, serum IgE tests like ImmunoCAP measure IgE against whole peanut extract. With the advent of component-resolved diagnosis (CRD), the potential of serum IgE testing to distinguish between tolerance and allergy, and beyond that, to better assess the risk of severe reactions, has significantly increased. In multiple studies, IgE to Ara h 2 has been reported to perform better than extract in discriminating peanut allergic patients from tolerant sensitized subjects, both in children [2] [3] [4] [5] [6] [7] [8] and adults. 9 More recently, IgE against Ara h 6 has been reported to perform similarly well as Ara h 2 as biomarker for peanut allergy. [10] [11] [12] [13] This is not surprising knowing that both allergens are closely related 2S albumins sharing (cross-reactive) IgE epitopes. 14 An association of IgE against Ara h 2 with symptom severity has also been reported, both in children and adults 6, 9, 15, 16 as well as it being a good discriminator between mild and severe symptoms, 12, 17 but there are also conflicting reports. 2, 7, 18, 19 Not only IgE against peanut extract but also against Ara h 2 can be found in peanut-tolerant subjects. We included 162 sensitized subjects that had undergone a food challenge to confirm or exclude peanut allergy, as previously described, 5 and of whom a blood sample was available that had been taken and stored within a year from the challenge. Twenty-five of the 162 patients were negative during their first challenges and of the remaining 137 positives, 42 were followed longitudinally with one or multiple re-challenges and matched blood samples. Six of these 42 patients later developed tolerance to peanut verified by a negative challenge. All children younger than 4 years of age and patients with compliance problems underwent OFCs (n = 122). All other patients had a DBPCFC (n = 40). In total, 212 challenges were performed of which 181(85.4%) were positive.
Details of the challenges and threshold doses were published elsewhere. 27 Patients were challenged with whole roasted unsalted peanuts under guidance of trained staff following the European Academy of Allergy and Clinical Immunology (EAACI) guidelines. 4 and IgA antibodies against whole peanut (extract) and peanut components rAra h 1 (7S globulin), rAra h 2 (2S albumin), rAra h 3(11S globulin), rAra h 8(Bet v1 homologue) and rAra h 9
(lipid transfer protein).
| Statistical analysis
Differences in patient characteristics and antibody serum levels were compared between tolerant and allergic subjects and between the severity of the allergic reactions (tolerant, grade I, II, III or IV). We Because correlation analyses were comparable when using random effect models to adjust for multiple testing, Spearman's rank correlation coefficients (rho) are reported for correlations between IgE, IgG, IgG 4 and IgA antibodies and the challenge cumulative dose. P-values were adjusted using Bonferroni correction for multiple testing.
For comparison of the discriminative performance of all antibody isotypes and the ratio's receiver operating characteristic curve (ROC) analysis was used. We calculated the area under the ROC curve (AUC) for discriminating between tolerant and allergic patients and for discriminating between patients with mild-to-moderate (tolerant, grade I-II) and patients with severe (grade III and IV) symptoms. We compared AUCs of the different antibodies isotypes/subclasses using DeLong tests. Of the patients with multiple challenges, only the initial challenge was included in the ROC analysis.
Finally, we selected the markers that performed best according to the ROC analysis. Optimal cut-off values corresponding to the best sensitivity and specificity are data-driven and consequently prone to bias. 30 Therefore, cut-off values were drawn from both a sensitivity and a specificity of 95%, respectively, or if not attainable closest to 95%. From these cut-offs, the corresponding specificity or sensitivity, and positive predictive values (PPV) and negative predictive values (NPV) were calculated. We used R software version 3.2.4
for all statistical analyses.
3 | RESULTS
| Patient characteristics
The age of the 162 patients ranged from 0.6-26.6 years, with a mean age of 6.5 (SD 4.4). The majority was younger than 18 years of age (157/162, 96.9%). Of the 181 positive challenges, the symptoms of 7 patients (3.9%) were classified as grade I, 56 (30.9%) as grade II, 92 (51.8%) as grade III and 26 (14.4%) as grade IV (Table 1) .
Overall, Ara h 2 was the most frequently recognized peanut allergen (82.1%), mainly in patients with grade II symptoms or higher (84%-100%, see also 
| Associations of antibody isotype levels with tolerance and different severity grades
IgE levels to peanut extract were significantly higher in allergic than tolerant subjects ( Figure 1A and Table S2 ) and increased significantly with severity (see Figure 1B and Table S2 ). The same was observed for IgE against Ara h 1-3, but not against Ara h 8 and Ara h 9. Overall, IgE responses against Ara h 2 were clearly the highest except in tolerant subjects and grade I patients (Table 1 and Figure 1 ). IgG antibody levels against peanut extract, Ara h 1 and Ara h 2, and IgG 4
against Ara h 2 were also significantly higher in allergic patients than tolerant subjects ( Figure 2 ) and increased with severity ( Figure 1 and Table S2 ). For IgA, no significant associations with tolerance or symptom severity were found (Table S2) . Finally, analyses were also performed for ratios of IgG, IgG 4 , IgA and total IgE over specific IgE (Figures 2 and 3 and Table S3 ). In all four cases ratios were significantly higher in tolerant than allergic subjects for peanut extract, Ara h 1-3 but not for Ara h 8 and Ara h 9. For the same allergens, all four ratios decreased along with increasing severity of symptoms.
Finally, we analyzed whether thresholds and/or cumulative dose for objective reactions during challenge were associated with severity.
Although the threshold dose for objective symptoms was not associated, there was a negative association of severity with the cumulative dose, independent from sIgE levels to peanut Table 1 . Only IgE against Ara h 2 showed significant but a weak negative correlation after Bonferroni correction with the cumulative dose (ρ−0.252, P = 0.001).
| Correlations between IgE and non-IgE antibody levels
Significant correlations of non-IgE isotypes with IgE were found for all allergens in case of IgG and IgG 4 , and for peanut extract, Ara h 1-3 for IgA ( Figure S1 and S2). The highest correlation coefficients (P < 0.002)
were found for IgE and IgG 4 against Ara h 1 (ρ = 0.728), Ara h 8 (ρ = 0.651) and Ara h 2(ρ = 0.625), and for IgE and IgG against whole peanut (ρ = 0.683), Ara h 1 (ρ = 0.582) and Ara h 2 (ρ = 0.531).
| Identification of peanut allergic patients and severity of peanut allergy
To evaluate the diagnostic potential of the different allergen-specific antibody isotypes and their ratios, ROC analysis was performed. The complete results of all ROC analysis are shown in Table S4 and S5 The total number of each group represent the total number of challenges resulting in that symptom grade. All 162 patients had at least on challenge. The 42 patients with more than one challenge can be in more than on group or more than one time in the same group. Doses are expressed in gram/peanut protein.
P-values were calculated by generalized and linear mixed-effect models to account for data from the same patient at different time-points. Significant values are indicated in bold.
IQR, interquartile range; LOAEL, lowest observed adverse effect level for objective symptoms.
DATEMA ET AL. in the online repository. To distinguish tolerant from allergic subjects, peanut-specific (AUC 0.86, 95% CI 0.79-0.92) and Ara h 2-specific IgE (AUC 0.91, 95% CI 0.87-0.96) performed significantly (P < 0.001) better than IgG, IgG 4 and IgA (AUC between 0.52 and 0.72) (Figure 4A ; Table S4 ).
Similar results were found when discriminating patients with a severe peanut allergy (grades III/IV) from those having mild-tomoderate symptoms (Grade I/II) or being tolerant ( Figure 4B ; Table S4 ). The AUCs were highest for IgE against Ara h 2 (0.80, CI95% 0.73-0.87) and peanut (0.74, CI95% 0.66-0.81). All other AUCs were ≤0.70. Antibody ratios did not provide a better diagnostic prognostic value compared to IgE alone ( Figure 5 and Table S5 ). AUCs were the same or slightly lower than of IgE alone.
F I G U R E 1 Peanut-specific antibody levels. Antibody levels are summarized for (A) tolerant vs allergic peanut-sensitized patients and (B) stratified for the severity of allergic reactions. The x-axis represents the serum antibody levels. The symbols and the lines indicate the geometric mean and the 95% confidence interval (CI) around that mean Thresholds for IgE and for the ratios of IgG and IgG 4 over IgE to achieve either optimal sensitivity (~95%) or optimal specificity (~95%) are summarized in Table S6 and S7 in the online repository.
At a threshold of 0.7 kU A /L for peanut extract and 0.2 kU A /L for Ara h 2, 95% of the allergic patients were correctly identified (sensitivity). However, the specificities at these thresholds were low (24%-52%). When calculating the highest attainable specificity, we found the best result for Ara h 2 using ≥1.3 kU A /L as the threshold.
This resulted in a specificity of 92%, sensitivity of 76%, and PPV and NPV of 98% and 41%, respectively. For the classification of severe patients, the specificity remained also low when the sensitivity was~95%.
| DISCUSSION
It has been reported earlier 15, 26 and now confirmed in the present study that the ratio of peanut-specific, and in particular of Ara h 2-specific IgG 4 over IgE antibody levels is higher in subjects that tolerate peanuts than in those that are allergic to peanuts. In several F I G U R E 2 Differences in peanut-specific IgG/IgE and IgG 4 /IgE ratios. Serum IgG 4 antibody ratios relative to IgE in (A) tolerant vs allergic peanut-sensitized patients and (B) stratified for the severity of allergic reactions. The symbols and the lines indicate the geometric mean and the 95% confidence interval (CI) around that mean studies, Ara h 2-specific IgE has been demonstrated to be a better diagnostic marker to predict a positive challenge than IgE against peanut extract.
2-9,12
We were interested to know whether ratios of specific IgG 4 over IgE could further improve diagnostic performance. By comparing a large group of patients with challenge-proven peanut allergy to tolerant peanut-sensitized subjects, we have now demonstrated that this is not the case. In the present study, the established dominant role of Ara h 2 for peanut allergy 31 was confirmed in group of 162 peanut-sensitized allergic and tolerant children and adolescents: by adding Ara h 2-specific IgG 4 into the equation and use ratios over Ara h 2-specific IgE, the diagnostic prognostic value compared to specific IgE alone did not improve.
In line with some earlier publications 6,9,12,15-17 but opposite to some others, 2,7,18,19 our study found clear support for an association between sensitization to Ara h 2 and symptom severity during challenge. Conflicting results in very similarly designed studies such as the study by Blumchen et al 18 and the present study may perhaps be explained by differences in stop-criteria during challenge. Here,
we extended the present and published observations in support of an association between Ara h2-specific IgE and symptom severity to demonstrate that it is a good diagnostic discriminator between mild and severe symptoms during challenge (AUC 0.80, 95% CI 0.73-0.87).
IgE against peanut allergens is overall higher in patients reacting to peanuts than those tolerating peanuts, especially in patients with more severe symptoms, but a large overlap between groups makes it difficult to accurately discriminate them from each other. The aim of the present study was to investigate whether specific IgG, IgG 4 and/ or IgA levels are related to challenge outcomes, and whether their measurement may help to improve on the predictive potential of serum IgE testing. Although still a matter of some debate, IgG 4 antibodies are generally thought to be (part of) the working mechanism of immunotherapy. 20 Also, natural exposure to environmental or dietary allergens induces IgG 4 antibodies. 32 Recently, the LEAP intervention study 25 showed that in young children in the early introduction intervention group exposed to peanut protein, decreased development of peanut allergy was associated with increased IgG 4 levels and IgG 4 /IgE ratios. The classical hypothesis is that specific IgG 4 antibodies play a protective role in allergic disease by blocking IgE binding to allergens. This would inhibit IgE-facilitated antigen presentation and activation of effector cells and could thus explain why some sensitized subjects do not have allergic symptoms to peanut. 20 We observed that in patients with peanut allergy, similar to IgE, specific IgG and IgG 4 levels against peanut Ara h 2 were higher in allergic than tolerant subjects and increased with symptom severity.
Although apparently contradicting with a protective role, higher levels An important aspect of this study is that these results reflect the situation in a highly specialized hospital with selected patients with high likelihood of having true peanut allergy. This consequently affects the PPV and NPV, since they are highly related to the prevalence of the outcome measure. All patients that are included have positive IgE against peanut extract and this will tend to overestimate the discriminatory accuracy of peanut extract but also of the other markers.
| CONCLUSION
In conclusion, specific IgG and IgG 4 antibody levels are higher in peanut allergic than in sensitized but tolerant subjects and levels F I G U R E 5 Receiver operating characteristic (ROC) curves for antibody ratios against peanut extract and Ara h 2. A, Predicting the outcome of a positive peanut challenge. B, Predicting outcome of a severe peanut allergy. The P-values indicate the difference in performance of the antibody ratios compared to sIgE alone increase with the severity of challenge-associated symptoms.
Although their ratios over specific IgE are inversely associated with a positive challenge and with symptom severity, these ratios do not translate into a better predictive accuracy than with specific IgE alone. Specific IgE against Ara h 2 is the best biomarker in peanut allergy diagnosis, both to distinguish allergic from tolerant sensitized subjects and to estimate the risk of severe reactions.
